A medical implant manufacturer will pay $2 million in fines and recoup nearly $600,000 in incentive-based compensation from four senior executives who allegedly manipulated the company’s financial statements, wrongdoing the Securities and Exchange Commission (SEC) said it identified through its earnings per share (EPS) initiative.
